{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04771130",
            "orgStudyIdInfo": {
                "id": "BGB-11417-103"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-003285-12",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of BGB-11417 in Participants With Myeloid Malignancies",
            "officialTitle": "A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology"
            ],
            "study": "a-study-of-bgb-in-participants-with-myeloid-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-05-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-02-23",
            "studyFirstSubmitQcDate": "2021-02-23",
            "studyFirstPostDateStruct": {
                "date": "2021-02-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) ."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia",
                "Myelodysplastic Syndromes",
                "Myelodysplastic/Myeloproliferative Neoplasm"
            ],
            "keywords": [
                "BGB-11417",
                "Azacitidine",
                "Posaconazole",
                "AML",
                "MDS",
                "MDS/MPN"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 260,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Parts 1 and 2: AML Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.",
                    "interventionNames": [
                        "Drug: BGB-11417",
                        "Drug: Azacitidine"
                    ]
                },
                {
                    "label": "Parts 1 and 2: MDS Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.",
                    "interventionNames": [
                        "Drug: Azacitidine",
                        "Drug: BGB-11417"
                    ]
                },
                {
                    "label": "Part 3: AML and MDS Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.",
                    "interventionNames": [
                        "Drug: BGB-11417",
                        "Drug: Azacitidine",
                        "Drug: Posaconazole"
                    ]
                },
                {
                    "label": "Part 3: AML and MDS Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.",
                    "interventionNames": [
                        "Drug: BGB-11417"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BGB-11417",
                    "description": "Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.",
                    "armGroupLabels": [
                        "Part 3: AML and MDS Cohorts",
                        "Parts 1 and 2: AML Cohorts"
                    ],
                    "otherNames": [
                        "Sonrotoclax"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Azacitidine",
                    "description": "Intravenous or subcutaneous administration for 7 days.",
                    "armGroupLabels": [
                        "Part 3: AML and MDS Cohorts",
                        "Parts 1 and 2: AML Cohorts",
                        "Parts 1 and 2: MDS Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Posaconazole",
                    "description": "Oral administration for 8 days on second cycle only.",
                    "armGroupLabels": [
                        "Part 3: AML and MDS Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BGB-11417",
                    "description": "Oral administration for 28 days on a 28-day cycle.",
                    "armGroupLabels": [
                        "Part 3: AML and MDS Cohort"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BGB-11417",
                    "description": "Oral administration for 10 or 21 days on a 28-day",
                    "armGroupLabels": [
                        "Parts 1 and 2: MDS Cohorts"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)",
                    "timeFrame": "Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)"
                },
                {
                    "measure": "Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs)",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate",
                    "description": "CR plus CRh will be defined as the proportion of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS Cohort: Modified Overall Response (mOR) Rate",
                    "description": "The mOR will be defined as the proportion of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable (AUC0-t) Of BGB-11417 When Co-administered With Posaconazole",
                    "timeFrame": "Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)"
                },
                {
                    "measure": "Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole",
                    "timeFrame": "Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)"
                },
                {
                    "measure": "Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Co-administered With Posaconazole",
                    "timeFrame": "Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)"
                },
                {
                    "measure": "Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs",
                    "timeFrame": "Cycle 2"
                },
                {
                    "measure": "Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs",
                    "timeFrame": "Approximately 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1 And 2 AML Cohort: CR Plus CRh Rate",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Parts 1 And 2 MDS Cohort: mOR Rate",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: t1/2 Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417",
                    "timeFrame": "Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine",
                    "timeFrame": "Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine",
                    "timeFrame": "Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine",
                    "timeFrame": "Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose"
                },
                {
                    "measure": "Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine",
                    "timeFrame": "Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose"
                },
                {
                    "measure": "Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3: Complete Response",
                    "description": "CR will be defined as the proportion of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate",
                    "description": "CRi will be defined as the proportion of participants whose BOR is CRi.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Overall Response Rate (ORR)",
                    "description": "The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Duration Of Response (DOR)",
                    "description": "DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Time To Response (TTR)",
                    "description": "TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Event-free Survival (EFS)",
                    "description": "EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Overall Survival (OS)",
                    "description": "OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML Cohort: Number of Participants with Transfusion Independence",
                    "description": "Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E)",
                    "description": "The proportion of participants whose BOR is HI-E",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P)",
                    "description": "The proportion of participants whose BOR is HI-P",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N)",
                    "description": "The proportion of participants whose BOR is HI-N will be reported.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS Cohort: Number of participants with Transfusion Independence",
                    "description": "Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine",
                    "timeFrame": "Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose)"
                },
                {
                    "measure": "Part 3 MDS cohort: Partial Hematologic Recovery CRh",
                    "description": "Proportion of participants with partial hematologic recovery will be reported",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery",
                    "description": "Proportion of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417",
                    "timeFrame": "Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)"
                },
                {
                    "measure": "Part 3 MDS (Treated with Monotherapy): Modified Overall Response",
                    "description": "Proportion of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR)",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417",
                    "timeFrame": "Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:\n\n   * AML, nonacute promyelocytic leukemia\n   * MDS\n   * MDS/MPN\n2. Eastern Cooperative Oncology Group performance status of 0 to 2.\n3. Adequate organ function defined as:\n\n   * Creatinine clearance \u2265 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)\n   * Adequate liver function\n4. Life expectancy of \\> 12 weeks.\n5. Ability to comply with the requirements of the study.\n\nKey Exclusion Criteria:\n\n1. A diagnosis of acute promyelocytic leukemia.\n2. Prior malignancy within the past 2 years, except for curatively treated localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score \u2264 6 prostate cancer.\n3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.\n4. Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine except for participants who meet HMA-failure criteria\n5. Known central nervous system involvement by leukemia.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BeiGene",
                    "role": "CONTACT",
                    "phone": "1.877.828.5568",
                    "email": "clinicaltrials@beigene.com"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope National Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Tampa General Hospital",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33606",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Maryland Oncology Hematology, Pa",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "Maryland",
                    "zip": "21044",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.24038,
                        "lon": -76.83942
                    }
                },
                {
                    "facility": "Upmc Hillman Cancer Center(Univ of Pittsburgh)",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Concord Repatriation General Hospital",
                    "status": "RECRUITING",
                    "city": "Concord",
                    "state": "New South Wales",
                    "zip": "2139",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.84722,
                        "lon": 151.10381
                    }
                },
                {
                    "facility": "St George Hospital",
                    "status": "RECRUITING",
                    "city": "Kogarah",
                    "state": "New South Wales",
                    "zip": "2217",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.98333,
                        "lon": 151.11667
                    }
                },
                {
                    "facility": "Orange Health Hospital",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "New South Wales",
                    "zip": "2800",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.28397,
                        "lon": 149.10018
                    }
                },
                {
                    "facility": "Gold Coast University Hospital",
                    "status": "RECRUITING",
                    "city": "Southport",
                    "state": "Queensland",
                    "zip": "4215",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                },
                {
                    "facility": "John Flynn Private Hospital",
                    "status": "RECRUITING",
                    "city": "Tugun",
                    "state": "Queensland",
                    "zip": "4224",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -28.15,
                        "lon": 153.5
                    }
                },
                {
                    "facility": "Monash Health",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3168",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "St Vincents Hospital Melbourne",
                    "status": "RECRUITING",
                    "city": "Fitzroy",
                    "state": "Victoria",
                    "zip": "3065",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.79839,
                        "lon": 144.97833
                    }
                },
                {
                    "facility": "Austin Health",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "state": "Victoria",
                    "zip": "3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.75,
                        "lon": 145.06667
                    }
                },
                {
                    "facility": "The Alfred Hospital",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Fiona Stanley Hospital",
                    "status": "RECRUITING",
                    "city": "Murdoch",
                    "state": "Western Australia",
                    "zip": "6150",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -32.06987,
                        "lon": 115.83757
                    }
                },
                {
                    "facility": "Linear Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "One Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "Peking University Peoples Hospital",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "state": "Beijing",
                    "zip": "100044",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "The First Hospital of Lanzhou University",
                    "status": "RECRUITING",
                    "city": "Lanzhou",
                    "state": "Gansu",
                    "zip": "730000",
                    "country": "China",
                    "geoPoint": {
                        "lat": 36.05701,
                        "lon": 103.83987
                    }
                },
                {
                    "facility": "Guangdong Provincial Peoples Hospital",
                    "status": "RECRUITING",
                    "city": "Guangzhou",
                    "state": "Guangdong",
                    "zip": "510080",
                    "country": "China",
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "Nanfang Hospital of Southern Medical University",
                    "status": "RECRUITING",
                    "city": "Guangzhou",
                    "state": "Guangdong",
                    "zip": "510515",
                    "country": "China",
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "The Second Peoples Hospital of Shenzhen",
                    "status": "RECRUITING",
                    "city": "Shenzhen",
                    "state": "Guangdong",
                    "zip": "518037",
                    "country": "China",
                    "geoPoint": {
                        "lat": 22.54554,
                        "lon": 114.0683
                    }
                },
                {
                    "facility": "Henan Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Zhengzhou",
                    "state": "Henan",
                    "zip": "450000",
                    "country": "China",
                    "geoPoint": {
                        "lat": 34.75778,
                        "lon": 113.64861
                    }
                },
                {
                    "facility": "Union Hospital of Tongji Medical College, Huazhong University of Science and Technology",
                    "status": "RECRUITING",
                    "city": "Wuhan",
                    "state": "Hubei",
                    "zip": "430022",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.58333,
                        "lon": 114.26667
                    }
                },
                {
                    "facility": "The First Affiliated Hospital of Soochow University",
                    "status": "RECRUITING",
                    "city": "Suzhou",
                    "state": "Jiangsu",
                    "zip": "215006",
                    "country": "China",
                    "geoPoint": {
                        "lat": 31.30408,
                        "lon": 120.59538
                    }
                },
                {
                    "facility": "The First Affiliated Hospital of Nanchang University Branch Donghu",
                    "status": "RECRUITING",
                    "city": "Nanchang",
                    "state": "Jiangxi",
                    "zip": "330006",
                    "country": "China",
                    "geoPoint": {
                        "lat": 28.68396,
                        "lon": 115.85306
                    }
                },
                {
                    "facility": "West China Hospital, Sichuan University",
                    "status": "RECRUITING",
                    "city": "Chengdu",
                    "state": "Sichuan",
                    "zip": "610041",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.66667,
                        "lon": 104.06667
                    }
                },
                {
                    "facility": "Tianjin Medical University Cancer Institute and Hospital",
                    "status": "RECRUITING",
                    "city": "Tianjin",
                    "state": "Tianjin",
                    "zip": "300060",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.14222,
                        "lon": 117.17667
                    }
                },
                {
                    "facility": "The First Affiliated Hospital, Zhejiang University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Hangzhou",
                    "state": "Zhejiang",
                    "zip": "310003",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.29365,
                        "lon": 120.16142
                    }
                },
                {
                    "facility": "Universitaetsklinikum Leipzig Aor",
                    "status": "RECRUITING",
                    "city": "Leipzig",
                    "zip": "04103",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "North Shore Hospital",
                    "status": "RECRUITING",
                    "city": "Takapuna",
                    "zip": "0622",
                    "country": "New Zealand",
                    "geoPoint": {
                        "lat": -36.79167,
                        "lon": 174.77583
                    }
                },
                {
                    "facility": "Wellington Regional Hospital (Ccdhb)",
                    "status": "RECRUITING",
                    "city": "Wellington",
                    "zip": "6021",
                    "country": "New Zealand",
                    "geoPoint": {
                        "lat": -41.28664,
                        "lon": 174.77557
                    }
                },
                {
                    "facility": "Hospital de La Santa Creu I Sant Pau",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08025",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen Del Rocio",
                    "status": "RECRUITING",
                    "city": "Sevilla",
                    "zip": "41013",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "Hospital Universitari I Politecnic La Fe",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46026",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "France",
                "Italy",
                "United Kingdom"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000054437",
                    "term": "Myelodysplastic-Myeloproliferative Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "relevance": "LOW"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27707",
                    "name": "Myelodysplastic-Myeloproliferative Diseases",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3994",
                    "name": "Myelodysplastic/myeloproliferative Disease",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000101425",
                    "term": "Posaconazole"
                },
                {
                    "id": "D000001374",
                    "term": "Azacitidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000935",
                    "term": "Antifungal Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000014344",
                    "term": "Trypanocidal Agents"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000058888",
                    "term": "14-alpha Demethylase Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "asFound": "Pilot Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M219015",
                    "name": "Posaconazole",
                    "asFound": "Sphincter",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}